MYCN is a novel oncogenic target in pediatric T-cell acute lymphoblastic leukemia.
about
MYCN-targeting miRNAs are predominantly downregulated during MYCN‑driven neuroblastoma tumor formation.EZH2 is increased in paediatric T-cell acute lymphoblastic leukemia and is a suitable molecular target in combination treatment approachesThe MYCN Protein in Health and Disease.MYCN is a novel oncogenic target in adult B-ALL that activates the Wnt/β-catenin pathway by suppressing DKK3.
P2860
MYCN is a novel oncogenic target in pediatric T-cell acute lymphoblastic leukemia.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
MYCN is a novel oncogenic target in pediatric T-cell acute lymphoblastic leukemia.
@en
MYCN is a novel oncogenic target in pediatric T-cell acute lymphoblastic leukemia.
@nl
type
label
MYCN is a novel oncogenic target in pediatric T-cell acute lymphoblastic leukemia.
@en
MYCN is a novel oncogenic target in pediatric T-cell acute lymphoblastic leukemia.
@nl
prefLabel
MYCN is a novel oncogenic target in pediatric T-cell acute lymphoblastic leukemia.
@en
MYCN is a novel oncogenic target in pediatric T-cell acute lymphoblastic leukemia.
@nl
P2093
P2860
P356
P1433
P1476
MYCN is a novel oncogenic target in pediatric T-cell acute lymphoblastic leukemia.
@en
P2093
Alberto M Martelli
Andrea Pession
Daniela Bressanin
Fraia Melchionda
Francesca Chiarini
Francesca Vendemini
Giuseppina Paone
Luca Montemurro
Marco Togni
Monica Franzoni
P2860
P304
P356
10.18632/ONCOTARGET.1337
P407
P577
2014-01-01T00:00:00Z